Clinical Trial Update: A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC) [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating CHF 5633 and poractant alfa in newborn respiratory distress syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome Newborn

Drugs mentioned

• CHF 5633
• Poractant alfa (poractant alfa)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Respiratory Distress Syndrome, Newborn | Phase 2 | Status: COMPLETED | Results posted: 2021-06-23